ex-vivo CRISPR autologous human-derived alpha-beta T-cell based gene therapy (Editas Medicine/Bristor-Myers Squibb)

N/A

Report date: 2025/03/20 16:00:02

Base Information

Drug Nameex-vivo CRISPR autologous human-derived alpha-beta T-cell based gene therapy (Editas Medicine/Bristor-Myers Squibb)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Stem cell therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy

Mechanisms of ActionT lymphocytes modulators

TargetsUpdating

Therapy Area/IndicationsSolid tumoursHematologic NeoplasmsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesEditas Medicine Inc

China Registration ClassN/A

Develop Information

Active CompaniesEditas Medicine Inc

Inactive CompaniesBristol-Myers Squibb Company

Active IndicationsSolid tumoursHematologic Neoplasms

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A